Department of Ophthalmology, Seoul National University College of Medicine and Seoul National University Hospital, Republic of Korea, Seoul, Korea.
Retinal Degeneration Laboratory, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Ocul Immunol Inflamm. 2022 Aug;30(6):1347-1353. doi: 10.1080/09273948.2021.1872652. Epub 2021 Apr 1.
To investigate the role of ultra-widefield fluorescein angiography (UWFA) for monitoring therapeutic response to adalimumab in patients with Behcet's uveitis.
Patients with Behcet's uveitis treated with adalimumab for ≥30 weeks were included. Intraocular inflammation, best-corrected visual acuity, systemic medications, and UWFA scores were evaluated.
Thirty-eight eyes of 20 patients were included. Significant decreases in grading of anterior chamber cells and vitreous haze were observed at 6, 14, and 30 weeks after adalimumab administration ( < .001 for all). UWFA scores on vascular and capillary leakage were decreased at week 6 and further improved at weeks 14 and 30. Moreover, UWFA score further decreased at 14 and 30 weeks, even after manifest inflammation became quiescent at 6 weeks. ( = .004 and 0.001, respectively).
UWFA scores significantly improved in Behcet's uveitis patients treated with adalimumab, and further improvement of UWFA scores was found in patients with a clinically quiescent inflammatory state.
探讨超广角荧光素血管造影（UWFA）在监测阿达木单抗治疗 Behcet 葡萄膜炎患者疗效中的作用。
纳入接受阿达木单抗治疗≥30 周的 Behcet 葡萄膜炎患者。评估眼内炎症、最佳矫正视力、全身药物和 UWFA 评分。
共纳入 20 例患者的 38 只眼。阿达木单抗治疗后 6、14 和 30 周，前房细胞和玻璃体混浊分级显著降低（均<0.001）。血管和毛细血管渗漏的 UWFA 评分在第 6 周降低，并在第 14 和 30 周进一步改善。此外，即使在第 6 周炎症明显静止后，第 14 和 30 周 UWFA 评分仍进一步降低（分别为=0.004 和 0.001）。
接受阿达木单抗治疗的 Behcet 葡萄膜炎患者的 UWFA 评分显著改善，在炎症临床静止的患者中发现 UWFA 评分进一步改善。
